The annual meeting of the American Academy of Orthopaedic Surgeons was held from March 10 to 14 in San Diego, drawing ...

If you believed everything you read on social media, you’d think HHS Secretary Robert F. Kennedy Jr. had issued a sweeping ...

Isaacs said she was pleased to see Novo Nordisk take a step toward improving access to semaglutide ... selling it in vials and having patients draw up the medication in syringes.

People often visit wellness tenants including gyms three to five times a week, he said, which may lead them to patronize ...

The Outsourcing Facilities Association is appealing a ruling that rejected their request for an injunction against the FDA’s declaration that the shortage of tirzepatide is over.

AI-powered digital pathology specialist PathAI, based in Boston in the US, said that AIM-NASH AI Assist is designed to assist ...

In the 2022 semaglutide trial, participants’ blood pressure readings went back up to pretreatment levels ... But Anekwe says it’s still too early to draw conclusions from the study, which ...

they can be more choosy about where they set up a practice. PDS Health likes local shopping centers that people who live nearby visit often, preferably with a big-box draw such as Target ...

The impending expiry of semaglutide patents is drawing interest from generic manufacturers ... Similarly, Biocon is advancing its version of semaglutide and is gearing up for clinical trials in India, ...

As I wrote in my last note on Structure: The most famous examples of GLP-1 agonist drugs are Novo Nordisk's (NVO) semaglutide - approved ... could also open up a large market opportunity even ...

Oversold indicators flashing as draw-down comparisons are made; Investors look to US CPI tomorrow. - European markets gained bullish momentum during first hour of trading, led by the DAX up ~1.0% ...

That's despite Novo's producing all of its weight-loss drug Wegovy's active pharmaceutical ingredient, semaglutide ... European patients could end up in the cross-hairs. Both the EU and the U.S. are ...